The Global Leigh Syndrome Treatment Market is expected to grow at a CAGR of approximately 6.5% during the forecast period 2017-2023

Market Research Future has a half-cooked research report on the global Leigh syndrome treatment market. Leigh Syndrome Treatment Market: Increasing Cases of Genetic Disorders is projected to Boost the Business at a CAGR of 6.5% During Forecast Period 2017-2023

Leigh’s disease is a progressive neurometabolic disorder occurring often after a viral infection during childhood, however, it can also occur in teens and adults. It is usually diagnosed with the help of MRI of the brain, particularly of the midbrain and brainstem part. The child often appears normal at birth but symptoms begin to appear within a few months to a period of two years of age. These may be accompanied by other problems such as irritability, loss of appetite, vomiting, and seizures. Eventually, the child may also have heart, kidney, vision, and breathing complications. There are different forms of Leigh's disease, but all forms have a poor prognosis. Those with partial deficiencies have a better prognosis but may live to be 6 or 7 years of age. Most cases are fatal during childhood, although some individuals have survived to adolescence.

Get a sample report at https://www.marketresearchfuture.com/sample_request/5249 .

Key Players

Some of key the players in the global Leigh syndrome treatment market are GlaxoSmithKline Plc (GSK), Brother Enterprises (China), Huazhong Pharma (China), Zhejiang Tianxin (China), Stryker Corporation (U.S.), Zimmer Biomet Holdings, Inc. (U.S.), Wright Medical Technology, Inc. (U.S.), Integra LifeSciences Holdings Corporation (U.S.), and others.

The most common underlying cause is a defect in energy production in the brain. Inborn errors of metabolism have also been reported with Leigh syndrome. According to researchers the classical form of Leigh syndrome accounted for approximately 80 percent of cases. The prevalence of Leigh syndrome has been estimated at 1 in every 36,000-40,000 births.

Regional Analysis

Global Leigh syndrome treatment consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East.

The Americas dominated the global Leigh syndrome treatment market owing to the rising incidences of genetic disorders. The European market holds the second largest share of the global Leigh syndrome treatment market owing to the high prevalence rate of this disease in the Eastern European regions. The Asia Pacific is expected to be the fastest growing region and is anticipated to compete with the American market during the forecasted period 2017-2023. The Middle East & African market especially, the African region is expected to witness a poor growth owing to the lack of knowledge in the medical sector, and less development in medical facilities in the Middle East & Africa will have limited growth in the market.

Browse Complete Report at https://www.marketresearchfuture.com/reports/leigh-syndrome-treatment-market-5249 .

The Leigh syndrome treatment is segmented on the basis of diagnosis, treatment, and end-users.

On the basis of the diagnosis, the market is segmented into magnetic resonance imaging (MRI), computed tomography (CT), laboratory test, and others. The laboratory test is divided into blood test, serum test, urine test, and others.

On the basis of the treatment, the market is segmented into medications, medical procedures, and surgery.

On the basis of the end-user, the market is segmented into hospital, research organizations, and academic institutes.

Leigh's disease can be caused by mutations in mitochondrial DNA or by deficiencies of an enzyme called pyruvate dehydrogenase. The risk of passing the abnormal gene from affected parent to offspring is 50 percent for each pregnancy. According to the United Mitochondrial Disease Foundation, the estimated incidence of Leigh’s disease is one in 77,000 births or one per 40,000 births for Leigh and Leigh-like disease. However, this may be an underestimate since mitochondrial diseases tend to be misdiagnosed. The disorders are due to a broad range of genetic mutations in both nuclear DNA (nDNA) and mitochondrial DNA (mtDNA).

The most common treatment for Leigh's disease is thiamine or Vitamin B1. Oral sodium bicarbonate or sodium citrate may also be prescribed to manage lactic acidosis. Currently, dichloroacetate is being tested to establish its effectiveness in treating lactic acidosis. Leigh disease occurs in at least 1 of 40,000 live births, though certain populations have much higher rates.

More Inquire at https://www.marketresearchfuture.com/enquiry/5249 .

Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. The market in the Asia Pacific is expected to witness the fastest growth rate within the forecast period due to increasing birth rates coupled with increasing number of genetic disorders. The developing countries are facing a poor prognosis, with death usually occurring in childhood. The later the onset, the slower the deterioration. Death is most frequently due to respiratory failure. The Middle East and Africa are also expected to show a healthy growth in the coming five years.

About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact us
Market Research Future
Maharashtra, India
+1 646 845 9312
Email: sales@Marketresearchfuture.Com

This release was published on openPR.